Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

por Assaad-Khalil, Samir Helmy, Najem, Robert, Sison, Jorge, Kitchlew, Asad Riaz, Cho, Belong, Ueng, Kwo-Chang, DiTommaso, Shelley, Shete, Abhijit
Publicado 2015

Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies

por Deodhar, Atul A., Miceli‐Richard, Corine, Baraliakos, Xenofon, Marzo‐Ortega, Helena, Gladman, Dafna D., Blanco, Ricardo, Das Gupta, Ayan, Martin, Ruvie, Safi, Jorge, Porter, Brian, Shete, Abhijit, Rosenbaum, James T.
Publicado 2020

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

por Elewski, Boni E., Baddley, John W., Deodhar, Atul A., Magrey, Marina, Rich, Phoebe A., Soriano, Enrique R., Soung, Jennifer, Bao, Weibin, Keininger, Dorothy, Marfo, Kwaku, Patekar, Manmath, Sharma, Abhishek, Shete, Abhijit, Lebwohl, Mark Gabriel
Publicado 2021

Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

por Braun, Jürgen, Blanco, Ricardo, Marzo-Ortega, Helena, Gensler, Lianne S., van den Bosch, Filip, Hall, Stephen, Kameda, Hideto, Poddubnyy, Denis, van de Sande, Marleen, Wiksten, Anna S., Porter, Brian O., Shete, Abhijit, Richards, Hanno B., Haemmerle, Sibylle, Deodhar, Atul
Publicado 2021

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Cl...

por GOTTLIEB, Alice B., DEODHAR, Atul, MCINNES, Iain B., BARALIAKOS, Xenofon, REICH, Kristian, SCHREIBER, Stefan, BAO, Weibin, MARFO, Kwaku, RICHARDS, Hanno B., PRICOP, Luminita, SHETE, Abhijit, TRIVEDI, Vivek, KEEFE, Deborah, PAPAVASSILIS, Charis C., JAGIELLO, Piotr, PAPANASTASIOU, Philemon, MEASE, Philip J., LEBWOHL, Mark
Publicado 2022